Background & Objectives: Pelvic inflammatory disease (PID) is a major health problem of reproductive age women in both developing and developed countries. About 10-20 per 1000 fertile women suffers from PID. The aim of the study was to evaluate the efficacy of arq brinjasif in mild pelvic inflammatory disease.
Method: A standard controlled randomised single blind study was carried out at the Institute’s Hospital, Bangalore. A total of 40 patients in the age group of 20-40 yrs with mild PID were randomly assigned to two equal groups to receive either arq brinjasif (test group) or combination of ofloxacin-ornidazole (control group) twice daily orally for 14 days. Primary outcome measures were clinical response, defined as 70% or more reduction in Visual Analogue Score (VAS) and McCormack pain scale (McPS) score after 2nd week of treatment with no clinical recurrence within 5 days. Secondary outcome measures were clinical cure, defined by absence or minimum pelvic tenderness and presence of clear vaginal discharge at the end of 4th week.
Results: Clinical response for VAS was achieved in 90% patients in test and 95% in control group with p =1.000 & for total tenderness in 75% patients in test and 95% in control group with p value=0.182. Pelvic tenderness was clinically cured in 90% patients in either group with p=1.000. Clear vaginal discharge was achieved in 95% patients in both groups with p=1.000.Interpretation and Conclusion: Effect of arq brinjasif was comparable to control drug in the management of mild PID & hence, can be used as an alternate therapy.